wherein R1 and R2 independently represent

- (i) $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl or $-C_{1-3}$ alkyl C_{3-8} cycloalkyl, or such a group in which alkyl or cycloalkyl is substituted by one or more halogen, CN, nitro, hydroxy or $-OC_{1-6}$ alkyl groups;
- (ii) $-(CH_2)_eAr^1$ or $-(CH_2)_eOAr^1$;

or NR¹R² together represent pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or azepinyl, or such a group fused to a benzene ring, optionally substituted by one or more -(CO)_n(CH₂)_tAr¹, -(CO)_nC₁₋₆ alkylAr¹Ar², -(CO)_nC₁₋₆alkyl, -(CH₂)_rOH, -(CH₂)_rO(CH₂)_pOH, $-(CH_2)_tOC_{1-6}$ alkyl, $-O(CH_2)_tAr^1$, $-(CH_2)_tSO_2Ar^1$, -NR¹⁰(CO)₀(CH₂)_tAr¹, -NR¹⁰(CO)₀C₁ piperidin-1-yl, -(CH₂)_tCONR⁸R⁹, 3alkylC₃₋₆ cycloalkyl, -NR¹⁰(CO)_nC₁₋₆ alkyldiC₃₋₆ cycloalkyl, -CONR¹⁰(CH₂)_tAr¹, halogen, -NHSO₂C₁₋₆alkyl, -SO₂NR¹⁰R¹¹, -SO₂C₁₋₆ alkyl or R³ represents -C₁₋₆alkylNHC(=NH)NH₂, -C₂₋₆alkenylNHC(=NH)NH₂, $-C_{2-6}$ alkynylNHC(=NH)NH₂, $-C_{1-6}$ alkylNR¹⁴R¹⁸, $-(CH_2)_hCONR^{14}R^{18}$, $-(CH_2)_hCOC_{1-6}$ alkyl, -(CH₂)_dCHNR¹⁸CONR²⁰R²¹, -(CH₂)_mNR¹⁸CONR¹⁴R¹⁸, -(CH₂)_dNR¹⁸Ar³, -(CH₂)_dCONR¹⁸Ar³. -(CH₂)_bCOOR¹⁸, -(CH₂)_cAr³, -O(CH₂)_cAr³, -(CH₂)_dCO(CH₂)_s Ar^3 or $-(CH_2)_dOAr^3$; or R³ represents -(CH₂)_c-2,4-imidazolidinedione, -(CH₂)_c(piperidin-4-yl), -

or R^3 represents -(CH₂)_c-2,4-imidazolidinedione, -(CH₂)_c(piperidin-4-yl), - (CH₂)_c(piperidin-3-yl), -(CH₂)_c(piperidin-2-yl), -(CH₂)_c(morpholin-3-yl) or - (CH₂)_c(morpholin-2-yl) optionally substituted on nitrogen by -(CO)_fC₁₋₆alkyl, - (CO)_f(CH₂)_cAr² or -C(=NH)NH₂;

or R^3 represents - $(CH_2)_z$ dibenzofuran optionally substituted by - C_{1-8} alkyl or halogen; or R^3 represents - $(CH_2)_c$ -thioxanthen-9-one;

 R^4 represents hydrogen, $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl C_{3-6} cycloalkyl, $-(CH_2)_qAr^2$, $-C_{1-4}$ alkyl-X- R^7 , $-C_{1-4}$ alkyl SO_2C_{1-4} alkyl, $-C_{1-6}$ alkylNR¹²R¹³ or $-C_{1-6}$ alkylNR¹²COC₁₋₆ alkyl; R^5 represents hydrogen, or R^4R^5 together with the carbon to which they are attached form a C_{5-7} cycloalkyl ring;

R⁶ represents hydrogen or -C₁₋₆alkyl, or R⁶ and R⁴ together with the N and C atoms to which they are respectively attached form a pyrrolidine ring;

 R^7 represents hydrogen, -(CH₂)_wNR¹²R¹³, -(CH₂)_uAr² or -(CH₂)_wNR¹²COC₁₋₆ alkyl; R^8 , R^9 , R^{16} and R^{17} independently represent hydrogen, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -C₁₋₃ alkylC₃₋₆ cycloalkyl, -C₂₋₆alkenyl or NR⁸R⁹ or NR¹⁶R¹⁷ together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or piperazinyl N-substituted by -C₁₋₆ alkyl, -COphenyl or -SO₂methyl;

 R^{10} , R^{11} , R^{12} , R^{13} , R^{15} , R^{18} , R^{20} and R^{21} independently represent hydrogen or $-C_{1-6}$

R¹⁴, R¹⁹ and R²² independently represent hydrogen, -C₁₋₆alkyl, -C₃₋₆ cycloalkyl or - (CH₂)_x Ar⁴ or NR¹⁴R¹⁸ or NR¹⁵R²² together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or N-C₁₋₆alkylpiperazinyl;

Ar¹ represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, C₁₋₆alkyl, hydroxy, -OC₁₋₆alkyl, CF₃, nitro, -Ar² or -OAr² groups; Ar² represents phenyl optionally substituted by one or more halogen, -C₁₋₆alkyl, hydroxy, -OC₁₋₆alkyl, -CF₃ or nitro groups;

Ar³ represents phenyl, a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S, or such a group fused to a benzene ring, optionally substituted by one or more $-CO(CH_2)_gAr^4$, $-(CH_2)_yAr^4$, $-(CH_2)_yCOAr^4$, $-(CO)_aC_{1-6}$ alkyl, $-(CO)_aC_{2-6}$ alkenyl, $-(CO)_aC_{2-6}$ alkynyl, $-(CO)_aC_{3-8}$ cycloalkyl, $-(CO)_aC_{1-6}$ haloalkyl, halogen, $-COCH_2CN$, $-(CH_2)_bNR^{16}R^{17}$, $-(CH_2)_b$ NHC(=NH)NH₂, $-CYNR^{16}(CO)_aR^{17}$, $-(CH_2)_bNR^{15}COR^{19}$, $-(CH_2)_bCONR^{15}R^{22}$, $-(CH_2)_bNR^{15}CONR^{15}R^{22}$, $-(CH_2)_bCONR^{15}(CH_2)_jNR^{15}R^{22}$, $-(CH_2)_bSO_2NR^{15}COAr^2$, $-(CH_2)_bNR^{15}SO_2R^{19}$, $-SO_2R^{19}$, $-SO_2R^{19}$, $-SO_2R^{19}$, $-(CH_2)_zOH$, $-COOR^{15}$, -CHO, $-OC_{1-10}alkyl$, $-O(CH_2)_jNR^{15}R^{22}$, $-O(CH_2)_jNHC(=NH)NH_2$, $-O(CH_2)_bCONR^{16}R^{17}$, $-O(CH_2)_kCOOR^{15}$, $-O(CH_2)_jOAr^2$, $-O(CH_2)_bAr^2$, 3-phenyl-2-pyrazolin-5-one or 4,5-dihydro-3(2H)-pyridazinone groups;

Ar⁴ represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, -C₁₋₆alkyl, hydroxy, -OC₁₋₆alkyl, -CF₃, nitro or -CONH₂ groups;

X and Y independently represent O or S;

- a, f, k, s and n independently represent 0 or 1;
- b, c, r, x, y and z independently represent an integer 0 to 2;
- d, g and u independently represent 1 or 2;
- e, h, q and w independently represent an integer 1 to 3;
- j and p independently represent an integer 2 to 4;

m independently represents an integer 0 to 4; t independently represents an integer 0 to 3; and salts and solvates thereof.

- 30. A compound according to claim 29 wherein R⁴ represents -C₁₋₆ alkyl, R⁵ represents hydrogen or R⁴R⁵, together with the carbon to which they are attached, forms a cyclohexyl ring, and R⁶ represents hydrogen or methyl.
- 31. A compound according to claim 30 wherein R^4 represents $-C_{1-6}$ alkyl and R^5 and R^6 represent hydrogen.
- 32. A compound according to claim 31 wherein R^4 represents - CH_2CHMe_2 and R^5 and R^6 represent hydrogen.
- 33. A compound according to claim 29 wherein NR¹R² together represents piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or 1,2,3,4-tetrahydroisoquinoline optionally substituted by a -(CO)_n (CH₂)_rAr¹, -(CO)_nC₁₋₆alkyl, -(CH₂)_tCONR⁸R⁹, NR¹⁰(CO)_n(CH₂)_rAr¹, -NR¹⁰ (CO)_nC₁₋₃ alkylC₃₋₆ cycloalkyl, -NR¹⁰(CO)_nC₁₋₆ alkyldiC₃₋₆ cycloalkyl, -(CH₂)_rOC₁₋₆ alkyl, -(CH₂)_rO(CH₂)_pOH, piperidin-1-yl, -(CH₂)_rOH or CONR¹⁰(CH₂)_rAr¹ group.
- 34. A compound according to claim 33 wherein NR^1R^2 together represents morpholinyl or piperazinyl optionally N-substituted by $-(CO)_nC_{1-6}$ alkyl, piperazinyl N-substituted by $-(CO)_n(CH_2)_rAr^1$, piperidinyl substituted by $-NR^{10}(CO)_n(CH_2)_rAr^1$ or piperidinyl substituted by $-(CH_2)_tCONR^8R^9$.
- 35. A compound according to claim 29 wherein R^3 represents - $(CH_2)_c$ -2,4-imidazolidinedione-3-yl, - $(CH_2)_c$ -thioxanthen-9-one-3-yl, - $(CH_2)_c$ Ar³, -O(CH₂)_cAr³, -(CH₂)_dOAr³ or - $(CH_2)_c$ dibenzofuran.
- 36. A compound according to claim 35 wherein R³ represents -OCH₂Ar³, -CH₂OAr³ or dibenzofuran.
- 37. A compound according to claim 36 wherein R³ represents -CH₂OAr³.
- 38. A compound according to claim 29 wherein R⁴ and R⁵ have the stereochemical orientation shown in formula (Ia):

$$R^4$$
 R^5 CO_2H R^1 (Ia)

39.

(2S)-2-[((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[((4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid; (2S)-2-({(2S)-4-Methyl-2-[(2-{[3-(1-piperidinylcarbonyl)-2-naphthyl] oxy}acetyl)amino]pentanoyl}amino)-3-{4-[((4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy]phenyl}propanoic acid;

(2S)-3-{4-[({4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-{[(2S)-4-methyl-2-({2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl} amino)pentanoyl]amino}propanoic acid;

(2S)-2-{[(2S)-4-Methyl-2-({2-[4-(1-piperidinylcarbonyl)phenoxy] acetyl}amino)pentanoyl]amino}-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl} propanoic acid;

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-{[(2S)-4-methyl-2-({2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl}amino)pentanoyl] amino}propanoic acid; (2S)-3-{4-[({4-[(2-Cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl) amino]propanoic acid; (2S)-3-{4-[({4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl) amino]propanoic acid; (2S)-2-(((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid; (2S)-2-(((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-{4-[(4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy] phenyl}propanoic acid;

3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy] phenyl}propanoic acid (2S)-2-[((2S)-2-{[2-(2-lodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy] phenyl}propanoic acid; (2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid; (2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid; (2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2,4-dichlorophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid; (2S)-3-[4-((4A-minesorbenyl) 4-methylpentanoyl)amino]propanoic acid; (2S)-3-[4-((4A-minesorbenyl) 4-minesidinyllacethoryl

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid; (2S)-2-{[(2S)-2-(2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-

3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

- (2S)-2-[((2S)-4-Methyl-2-{[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino]-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid; (2S)-2-({(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid; (2S)-2-{[(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl]amino}-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}
- (2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-(4-{[(4-{[(4-{[(4-{[(4-{[(4-{[(a-{idorobenzyl}]oxy}phenyl)propanoic acid;

oxy)phenyl]propanoic acid;

- (2S)-2-[((2S)-2-{[2-(2,4-Dichlorophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-2-[((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-2-[((2S)-4-Methyl-2-{[2-(2-propylphenoxy)acetyl]amino} pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-2-{[(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl]amino}-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-2-[((2S)-2-{[(Benzyloxy)carbonyl]amino}-4-methylpentanoyl) amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-3-[4-({[4-(2-Furoyl)-1-piperazinyl]carbonyl}oxy)phenyl]-2-[((2S) -2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acia;
- (2S)-2-[((2S)-2-{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;
- (2S)-2-{[(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl]amino}-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;
- (2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;
- (2S)-2-[((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-(4-{[(4-{[2-(4-chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)propanoic acid;
- (2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]propanoic acid;

 $(2S)-2-\{[(2S)-2-(\{2-[2-(Tert-butyl)phenoxy]acetyl\}amino)-4-methyl pentanoyl]amino\}-3-(4-\{[(4-\{[2-(4-chlorophenyl)acetyl]amino\}-1-piperidinyl)$

carbonyl]oxy}phenyl)propanoic acid;

(2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-

methylpentanoyl}amino)propanoic acid;

(2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-(((2S)-4-methyl-2-[(2-{[3-(1-piperidinylcarbonyl)-2-

naphthyl]oxy}acetyl)amino]pentanoyl}amino)propanoic acid;

(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[({4-[(2-cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid;

(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[({4-[(2,2-dicyclohexylacetyl)amino]-1-piperidinyl} carbonyl)oxy]phenyl}propanoic acid;

(2S)-2-[((2S)-4-Methyl-2-{[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid; (2S)-2-[((2S)-2-{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid; (2S)-3-{4-[({4-[(2-Cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-[((2S)-2-{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]propanoic acid;

and salts and solvates thereof.

- 40. A compound of formula (I) which is:
- (2S)-2-[((2S)-2-{[2-(2-lodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-{[(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}propanoic acid;
- (2S)-2-[((2S)-2-{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy] phenyl}propanoic acid; (2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-{[(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}propanoic acid;

(2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino)propanoic acid; (2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid; (2S)-2-({(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid; (2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid; (2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino)propanoic acid; and salts and solvates thereof.

- 41. A compound of formula (I) which is:
- (2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid;
- (2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-({(2S)-2-

[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino) propanoic acid;

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-{[(2S)-2-({2-[2-

(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino} propanoic acid;

- (2S)-2-[((2S)-4-Methyl-2-{[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
- (2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-2-{[2-(2-benzoylphenoxy)acetyl]amino}-4-methylpentanoyl)amino] propanoic acid; (2S)-2-{[(2S)-2-({2-[4-(Aminocarbonyl)phenoxy]acetyl}amino)-4-

methylpentanoyl]amino}-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

and salts and solvates thereof.

- 42. A compound of formula (I) which is:
- (2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid or a salt or solvate thereof.
- 43. A compound of formula (I) according to claim 42 which is: (2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid potassium salt or a solvate thereof.
- A pharmaceutical composition comprising a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.

- 45. A pharmaceutical composition comprising a compound of formula (I) according to claim 29 or a physiologically acceptable salt or solvate thereof in combination together with a long acting β_2 adrenergic receptor agonist.
- 46. A compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof for use as a pharmaceutical.
- 47. A method of treatment or prophylaxis of inflammatory diseaseseg. asthma which comprises administering to a patient an effective amount of a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof.
- 48. A process for preparation of a compound of formula (I) as defined in claim29 which comprises
- (a) hydrolysis of a carboxylic acid ester of formula (II)

$$R^3$$
 R^4
 R^5
 CO_2R
 R^1
 R^1
 R^1
 R^1

wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester; or

- (b) deprotecting a compound of formula (I) which is protected.
 - 49. A compound of formula (II)

$$R^3$$
 R^4
 R^5
 CO_2R
 R^1
 R^1
 R^1
 R^1

wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester.

50. A compound of formula (VI)

wherein P₁ represents Boc, R⁴, R⁵ and R⁶ are as defined in claim 29, and R represents a group capable of forming a carboxylic acid ester.

51. A compound of formula (VII)

$$R^4$$
 R^5 CO_2R O N R^1 $(VIII)$

wherein P_1 represents Boc, R^1 , R^2 , R^4 , R^5 and R^6 are as defined in claim 29, and R represents a group capable of forming a carboxylic acid ester.

52. A compound of formula (VIII)

$$R^4$$
 R^5 CO_2R O R^1 $(VIIII)$

wherein R^1 , R^2 , R^4 , R^5 and R^6 are as defined in claim 29, HX is a hydrohalic acid and R represents a group capable of forming a carboxylic acid ester.

53. A compound of formula (XIII)

wherein R⁴, R⁵ and R⁶ are as defined in claim 29 and R' represents a hydroxy functionalised polystyrene resin.